Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 5
Submit an article Journal homepage
1,369
Views
11
CrossRef citations to date
0
Altmetric
Research Article

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

Yiling Jiang Amaris, 1 Water Lane, London NW1 8NZ, UK; Amaris, 1 Water Lane, London NW1 8NZ, UK. [email protected]
,
Aline Gauthier Amaris, 1 Water Lane, London NW1 8NZ, UK
,
Lieven Annemans Ghent Univiersity, De Pintelaan 185, 9000 Ghent, Belgium; Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium
,
Mark van der Linden National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
,
Laurence Nicolas-Spony Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon CEDEX 07, France
&
Xavier Bresse Sanofi Pasteur MSD, 8, rue Jonas Salk, 69367 Lyon CEDEX 07, France
Pages 631-643 | Published online: 09 Jan 2014

References

  • Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin. Respir. Crit. Care Med. 30(2), 189–209 (2009).
  • Prato R, Tafuri S, Fortunato F, Martinelli D. Why it is still important that countries know the burden of pneumococcal disease. Hum. Vaccin. 6(11), 918–921 (2010).
  • Cartwright K. Pneumococcal disease in Western Europe: burden of disease, antibiotic resistance and management. Eur. J. Pediatr. 161(4), 188–195 (2002).
  • No authors listed. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly. Epidemiol. Rec. 83(42), 373–384 (2008).
  • Reinert RR, Haupts S, van der Linden M et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001–2003. Clin. Microbiol. Infect. 11(12), 985–991 (2005).
  • Hülsse C, Littmann M, Fiedler K, Kaltofen U, Hundt C. Epidemiologic and serologic studies of pneumococcal infections with reference to the new STIKO recommendations. Gesundheitswesen 61(8-9), 393–397 (1999).
  • Fedson DS, Nicolas-Spony L, Klemets P et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev. Vaccines 10(8), 1143–1167 (2011).
  • Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill. 10(9), 174–178 (2005).
  • No authors listed. Bekanntmachungen des Bundesgesundheitsamtes. Bundesgesundhbl. 25(5), 170–171 (1982).
  • No authors listed. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: März 1998. Epid. Bull. 15, 101–114 (1998).
  • Varon E. Epidemiology of acute bacterial meningitis in adult patients in France. Med. Mal. Infect. 39(7-8), 432–444 (2009).
  • Trotter CL, Waight P, Andrews NJ et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J. Infect. 60(3), 200–208 (2010).
  • Imöhl M, Reinert RR, van der Linden M. Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int. J. Microbiol. 2010, 874189 (2010).
  • van der Linden M, Imohl M. R2762 serotype distribution among bacteraemic pneumococcal pneumonia in adults in Germany. Clin. Microbiol. Infect. 17(S4), S832 (2011).
  • Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 1, CD000422 (2008).
  • Rodriguez-Barradas MC, Goulet J, Brown S et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin. Infect. Dis. 46(7), 1093–1100 (2008).
  • Peñaranda M, Falco V, Payeras A et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case–control study. Clin. Infect. Dis. 45(7), e82–e87 (2007).
  • Musher DM, Manof SB, Liss C et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J. Infect. Dis. 201(4), 516–524 (2010).
  • Hammitt LL, Bulkow LR, Singleton RJ et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 29(12), 2287–2295 (2011).
  • Smith KJ, Zimmerman RK, Lin CJ et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost–effectiveness analysis. Vaccine 26(11), 1420–1431 (2008).
  • Evers SM, Ament AJ, Colombo GL et al. Cost–effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur. J. Clin. Microbiol. Infect. Dis. 26(8), 531–540 (2007).
  • Ament A, Baltussen R, Duru G et al. Cost–effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31(2), 444–450 (2000).
  • Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost–effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 28(48), 7620–7625 (2010).
  • Kawakami K, Ohkusa Y, Kuroki R et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28(43), 7063–7069 (2010).
  • Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost–effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 27(36), 4891–4904 (2009).
  • Akin L, Kaya M, Altinel S, Durand L. Cost of pneumococcal infections and cost–effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum. Vaccin. 7(4), 441–450 (2011).
  • Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost–effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138(12), 960–968 (2003).
  • Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost–effective. Clin. Infect. Dis. 33(12), 2078–2079 (2001).
  • Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev. Pharmacoecon. Outcomes Res. doi:10.1586/ERP.12.54 (2012) (Epub ahead of print).
  • No authors listed. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI vom Juli 2006. Epid. Bull. 32, 271–276 (2006).
  • Sanofi Pasteur MSD data on file (2011).
  • No authors listed. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly. Epidemiol. Rec. 82(12) 93–104 (2007).
  • No authors listed. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly. Rep. 59(9), 258–261 (2010).
  • Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J. Infect. Dis. 197(11), 1511–1518 (2008).
  • Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187–195 (2000).
  • Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children – use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 59(RR-11), 1–18 (2010).
  • O’Brien KL. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We’re not there yet. Clin. Infect. Dis. 49(9), 1326–1328 (2009).
  • European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2010. ECDC, Stockholm, Sweden (2010).
  • Pilishvili T, Lexau C, Farley MM et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010).
  • Ardanuy C, Domenech A, Rolo D et al. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993–2008). J. Antimicrob. Chemother. 65(4), 634–643 (2010).
  • No authors listed. Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly. Epidemiol. Rec. 85(43), 434–436 (2010).
  • Hanage WP, Finkelstein JA, Huang SS et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2(2), 80–84 (2010).
  • Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines 8(10), 1351–1364 (2009).
  • Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11(10), 760–768 (2011).
  • Hanage WP. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol. 3(1), 23–30 (2008).
  • Annemans L. Progress in vaccines, progress in health economics. Vaccine 28(Suppl. 6), G1–G2 (2010).
  • Weinstein MC, O’Brien B, Hornberger J et al. ISPOR Task Force on Good Research Practices–Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 6(1), 9–17 (2003).
  • No authors listed. Mitteilung der Ständigen Impfkommission am Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2011. Epid. Bull. 30, 275–294 (2011).
  • Vila-Córcoles A, Ochoa-Gondar O, Hospital I et al. EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis. 43(7), 860–868 (2006).
  • Middleton DB, Lin CJ, Smith KJ et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect. Control Hosp. Epidemiol. 29(5), 385–394 (2008).
  • Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325(21), 1453–1460 (1991).
  • Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784–1792 (2007).
  • Manoff SB, Liss C, Caulfield MJ et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J. Infect. Dis. 201(4), 525–533 (2010).
  • Claes C, Reinert RR, von der Schulenburg JM. Cost–effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur. J. Health Econ. 10(1), 25–38 (2009).
  • Schulze-Gattermann H, Illg A, Schoenermark M, Lenarz T, Lesinski-Schiedat A. Cost–benefit analysis of pediatric cochlear implantation: German experience. Otol. Neurotol. 23(5), 674–681 (2002).
  • Kyaw MH, Rose CE Jr, Fry AM et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis. 192(3), 377–386 (2005).
  • Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24(47-48), 6812–6822 (2006).
  • Jansen AG, Rodenburg GD, de Greeff SC et al. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 27(17), 2394–2401 (2009).
  • Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 6(5), e1000081 (2009).
  • Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 64(12), 1062–1069 (2009).
  • Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin. Respir. Crit. Care Med. 30(2), 127–135 (2009).
  • des Portes V. Long-term follow-up of bacterial meningitis - sequels in children and adults: incidence, type, and assessment issues. Med. Mal. Infect. 39(7-8), 572–580 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.